Sachs D, Villarreal Cf, Cunha Fq, Parada Ca, Ferreira Sh
Department of Pharmacology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
Br J Pharmacol. 2009 Mar;156(5):826-34. doi: 10.1111/j.1476-5381.2008.00093.x. Epub 2009 Feb 13.
Protein kinase (PK) A and the epsilon isoform of PKC (PKCepsilon) are involved in the development of hypernociception (increased sensitivity to noxious or innocuous stimuli) in several animal models of acute and persistent inflammatory pain. The present study evaluated the contribution of PKA and PKCepsilon to the development of prostaglandin E(2) (PGE(2))-induced mechanical hypernociception.
Prostaglandin E(2)-induced mechanical hypernociception was assessed by constant pressure rat paw test. The activation of PKA or PKCepsilon was evaluated by radioactive enzymic assay in the dorsal root ganglia (DRG) of sensory neurons from the hind paws.
Hypernociception induced by PGE(2) (100 ng) by intraplantar (i.pl.) injection, was reduced by i.pl. treatment with inhibitors of PKA [A-kinase-anchoring protein St-Ht31 inhibitor peptide (AKAPI)], PKCepsilon (PKCepsilonI) or adenylyl cyclase. PKA activity was essential in the early phase of the induction of hypernociception, whereas PKC activity was involved in the maintenance of the later phase of hypernociception. In the DRG (L4-L5), activity of PKA increased at 30 min after injection of PGE(2) but PKC activity increased only after 180 min. Moreover, i.pl. injection of the catalytic subunit of PKA induced hypernociception which was markedly reduced by pretreatment with an inhibitor of PKCepsilon, while the hypernociception induced by paw injection of PKCepsilon agonist was not affected by an inhibitor of PKA (AKAPI).
Taken together, these findings are consistent with the suggestion that PKA activates PKCepsilon, which is a novel mechanism of interaction between these kinases during the development of PGE(2)-induced mechanical hypernociception.
蛋白激酶(PK)A和蛋白激酶C(PKC)的ε亚型(PKCε)在多种急性和持续性炎性疼痛动物模型的痛觉过敏(对有害或无害刺激的敏感性增加)发展过程中发挥作用。本研究评估了PKA和PKCε在前列腺素E2(PGE2)诱导的机械性痛觉过敏发展中的作用。
通过恒压大鼠 paw 试验评估PGE2诱导的机械性痛觉过敏。通过放射性酶法在来自后爪感觉神经元的背根神经节(DRG)中评估PKA或PKCε的激活情况。
足底注射(i.pl.)100 ng PGE2诱导的痛觉过敏,通过i.pl.给予PKA抑制剂[A激酶锚定蛋白St-Ht31抑制肽(AKAPI)]、PKCε抑制剂(PKCεI)或腺苷酸环化酶抑制剂可减轻。PKA活性在痛觉过敏诱导的早期阶段至关重要,而PKC活性参与痛觉过敏后期阶段的维持。在DRG(L4-L5)中,注射PGE2后30分钟PKA活性增加,但PKC活性仅在180分钟后增加。此外,i.pl.注射PKA的催化亚基诱导痛觉过敏,而用PKCε抑制剂预处理可显著减轻,而爪注射PKCε激动剂诱导的痛觉过敏不受PKA抑制剂(AKAPI)的影响。
综上所述,这些发现与PKA激活PKCε的观点一致,这是在PGE2诱导的机械性痛觉过敏发展过程中这些激酶之间相互作用的一种新机制。